In the treatment of CMO secondary to CRVO, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents: Ranibizumab, aflibercept, and unlicensed bevacizumab have consistently been shown to be efficacious in improving both anatomical and functional outcomes for patients [3–7]. Here, VEGFA is linked to chronic recurrent multifocal osteomyelitis.